(Q48266324)

10 February 2018

title

Controlled Fab-arm exchange for the generation of stable bispecific IgG1. (English)

1 reference

10 February 2018

author

Aran F Labrijn

1

1 reference

10 February 2018

Rob N de Jong

4

1 reference

10 February 2018

Paul Whi Parren

9

1 reference

10 February 2018

Janine Schuurman

object named as

Janine Schuurman

8

0 references

author name string

Joyce I Meesters

2

1 reference

10 February 2018

Patrick Priem

3

1 reference

10 February 2018

Ewald T J van den Bremer

5

1 reference

10 February 2018

Muriel D van Kampen

6

1 reference

10 February 2018

Arnout F Gerritsen

7

1 reference

10 February 2018

publication date

25 September 2014

1 reference

10 February 2018

published in

Nature Protocols

1 reference

10 February 2018

volume

9

1 reference

10 February 2018

issue

10

1 reference

10 February 2018

page(s)

2450-2463

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1038/nprot.2014.169

exact match

0 references

cites work

Dual targeting strategies with bispecific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Aggregation, stability, and formulation of human antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Therapeutic antibodies for autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

A simple, robust and highly efficient transient expression system for producing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Hybrid hybridomas and their use in immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPROT.2014.169

Bispecific antibodies for cancer therapy

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25255089

12 December 2020

inferred from PubMed ID database lookup

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25255089

12 December 2020

inferred from PubMed ID database lookup

Antibody therapeutics, antibody engineering, and the merits of protein stability

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25255089

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NPROT.2014.169

1 reference

10 February 2018

release_726leiqm4fg77foqefoo6dheje

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/726leiqm4fg77foqefoo6dheje

24 November 2022

mapped directly with Wikidata item

PubMed ID

25255089

1 reference

10 February 2018